echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > New England: Platelet factor 4 antibody produced after the first dose of AstraZeneca vaccination leads to thrombosis

    New England: Platelet factor 4 antibody produced after the first dose of AstraZeneca vaccination leads to thrombosis

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Vaccination against SARS-CoV-2 is the main means to control the Covid-19 pandemic.


    A particularly noteworthy safety signal related to the use of the ChAdOx1 novel coronavirus -19 vaccine (AstraZeneca) was recently reported, involving abnormal clinical coagulation abnormalities, especially cerebral venous thrombosis and thrombocytopenia, which in some cases caused death.


    Thrombosis Management

    The study reported 23 patients with thrombosis and thrombocytopenia 6 to 24 days after the first vaccination of ChAdOx1nCoV-19 vaccine (AstraZeneca).


    immunity

    Vaccination of SARS-CoV-2 vaccine is still the key to controlling the epidemic of new coronary pneumonia .


    Coronavirus disease

    The figure shows the flow cytometry analysis of the results of functional heparin-induced thrombocytopenia (HIT).


    The figure shows the flow cytometry analysis of the results of functional heparin-induced thrombocytopenia (HIT).


    An algorithm for the detection and treatment of patients with thrombosis and thrombocytopenia 5-30 days after vaccination.


    An algorithm for the detection and treatment of patients with thrombosis and thrombocytopenia 5-30 days after vaccination.


    In all cases reported so far, this thrombocytopenia and venous thrombosis syndrome appears to be triggered by receiving the first dose of the ChAdOx1 novel coronavirus -19 vaccine .


    This thrombocytopenia and venous thrombosis syndrome appears to be a diagnostic infection triggered by receiving the first dose of ChAdOx1 novel coronavirus-19 vaccine

    The risk of Covid-19 is still an important consideration for global public health.


    Original source:

    Scully Marie,Singh Deepak,Lown Robert et al.


    Scully Marie,Singh Deepak,Lown Robert et al.
    Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
    [J] .
    N Engl J Med, 2021, undefined: undefined.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.